A new study published this week by researchers at the University of California, San Diego highlights how Apple Vision ...

Stifel raised the firm’s price target on Vertex (VERX) to $52 from $41 and keeps a Buy rating on the shares following what the firm calls ...

BMO Capital raised the firm’s price target on Vertex (VERX) to $52 from $42 and keeps a Market Perform rating on the shares after its Q3 earnings beat. The company delivered good results with upside ...

Operator Good day, and welcome to the Vertex Pharmaceuticals third quarter 2024 earnings call. All participants will be in a ...

Apple is reportedly reducing Vision Pro production, but that doesn't mean it's out of the headset game. On Monday, The Information reported that Apple has been scaling back production of the $ ...

Vertex has reported phase 3 data on its near-approval pain drug candidate suzetrigine, shedding light on how the non-opioid painkiller combines with ibuprofen and why the prospect failed to match ...

Apple Vision Pro entered the market in January 2024 on a wave of hype almost unmatched in consumer technology. Tom's Guide's global Editor in Chief Mark Spoonauer called it a "revolution in ...

Vertex's diverse pipeline, including Casgevy for SCD, suzetrigine for chronic pain, and the vanzacaftor triple for CF, positions it for growth despite launch challenges. Casgevy's complex ...

Impact Link Where are the apps? Specifically: Where are the apps for the Apple Vision Pro, the $3,500 headset Apple introduced earlier this year? This is a question we've asked repeatedly ...

During an event for Tesla’s new self-driving Cybercab—due out 2027—Musk revealed an expansive vision for cities transformed by a robotaxi revolution. Experts say the plan has some hitches.